Calliope Bio uses microbial diversity to unlock the promise of natural products. We are an impact-oriented public benefit corporation developing synthetic biology tools to address critical issues in health, food security, and sustainability.
A search engine for nature
Accelerating Discovery
Immediate tractability of engineering diverse microbes and biosynthetic pathways to unlock synthetic biology solutions
Elevating Bioproduction
Using nature’s own built in diversity to unlock solutions to biosynthetic challenges
Streamlining Workflow
Our vertically integrated proprietary platform combines computational design with genetic designs appropriate for diverse host microbes
Nucleate Accelerator Team
Jaymin Patel
Ph.D., Yale University
Laura Quinto
Ph.D. Candidate, Yale University
Jonathan Sun
Ph.D. Candidate, Yale University
Kevin Christopher
M.B.A. Candidate, Yale University
Mentor Team
Hyde Patterson
Longitude Capital
Themasap Khan
Civilization Ventures
Colin Ng
AtlasXomics
Latest News
Calliope wins first place in Nucleate New Haven pitch competition and Alnylam Award for Scientific Excellence
In a culmination of the Nucleate Activator Program, Calliope pitched to a panel of VC judges and was awarded first place, qualifying them us to advance to pitch at the…
Read More
Calliope is accepted into the Berkeley SkyDeck Pad-13 Incubator cohort!
With access to over 50 workshops and world-renowned mentors, the Pad-13 program incubates early-stage startups with the potential to graduate to the Skydeck Accelerator program, which boasts high success rates…
Read More
Calliope Bio is accepted to the Nucleate Activator program
Advised by visionary scientists, entrepreneurs, investors, and founders, Nucleate fosters the formation of pioneering biotech ventures. With an exceptional track record of successful spin-out and VC fundraising, Nucleate is accelerating…
Read More